The Chinese government has been deepening its reform over the past year in order to foster evolving regulatory framework. Deeper reforms coupled with a chilled market means life science companies should prioritize their assets and re-position their business strategies in order to survive and grow stronger.
Deep synthesis involving editing of biometric information of individuals requires their separate consent
Charles Wu and Zaiguang Lu of Han Kun Law Offices review the significant legislative developments of 2022 affecting China's private equity and venture capital industry, and offer insights into the key trends, challenges and opportunities in the sector
Proposed amendments to Trademark Law combats malicious registration; China issues new rules on deep synthesis technology; and First local GI regulations bring hope to local businesses
China opens treasury bond futures to foreign bank; no protection for crypto investment; and ORFS bring Hong Kong in line with other major arbitration centers
Pinduoduo and Full Truck Alliance continue to list in the U.S.; Chinese companies raised far more money in Europe than U.S. in 2022; and official reports show promising improvements to China's IP systems
Article 9 on tech import and export record filing is removed
After a busy year on the capital markets, Haiping Li and Paloma Wang of Skadden Arps Slate Meagher & Flom LLP take a look at 2022's developments and what the next 12 months may hold.
U.S. gains full access to audits of Chinese companies; Fidelity targets China's mutual fund industry following the opening up of China's private pension industry; and China connects with Germany for overseas listings.
Anti-unfair competition law draft prohibits improper use of others' commercial data
